argenx

About argenx

argenx is a global immunology company committed to improving the lives of patients through innovative immunology solutions. Their mission is driven by the science of co-creation and the resilient spirit of patients, aiming to deliver life-changing therapies for severe autoimmune diseases. The infinity sign symbolizes their boundless commitment to science and patients.

Products & Services

Efgartigimod (VYVGART and VYVGART Hytrulo):Marketed for the treatment of generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). Designed to block FcRn and reduce IgGs, it targets severe autoimmune diseases.

Empasiprubart:Under evaluation for severe IgM-driven autoimmune diseases. It is a humanized sweeping antibody intended to inhibit C2 and downstream complement activation.

Specialties

Immunology Antibody Engineering Autoimmune Disease Treatment Collaboration in Science

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Global Offering T: - FT: Global Offering	A: 1270000000 MR: - FA: approximately $1.27 billion FAN: 1270000000	D: 2023-07-24 FD: 2023-07-24	6 investors
2	RT: Public Offering T: - FT: Public Offering	A: 1270000000 MR: - FA: 1.27 billion FAN: 1270000000	D: 2023-07-19 FD: 2023-07-19	6 investors
3	RT: Global Offering T: - FT: Global Offering	A: 1100000000 MR: - FA: approximately $1.1 billion FAN: 1100000000	D: 2023-07-18 FD: 2023-07-18	6 investors
4	RT: Global Offering T: - FT: Global Offering	A: 750000000 MR: - FA: $750 million FAN: 750000000	D: 2023-07-17 FD: 2023-07-17	1 investors

Global Offering Latest

2023-07-24

$1.3B

6 investors (Pro only)

Public Offering 2023-07-19

$1.3B

Global Offering 2023-07-18

$1.1B

View 3 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

T

Tim Van Hauwermeiren

Co-Founder, Chief Executive Officer

K

Karen Massey

Chief Operating Officer

K

Karl Gubitz

Chief Financial Officer

P

Peter Ulrichts

Chief Scientific Officer

M

Malini Moorthy

General Counsel

L

Luc Truyen

Chief Medical Officer

View 20 more team members with Pro

Unlock Full Team Directory

Recent News

argenx Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised